Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.04.2023 | Case report

Multiple drugs

Infections and off-label use: 3 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Shirai T, et al. Intensive induction therapy combining tofacitinib, rituximab and plasma exchange in severe anti-melanoma differentiation-associatedprotein-5 antibody-positive dermatomyositis. Clinical and Experimental Rheumatology 41: 291-300, No. 2, Feb 2023. Available from: URL: http://doi.org/10.55563/clinexprheumatol/8kulbf Shirai T, et al. Intensive induction therapy combining tofacitinib, rituximab and plasma exchange in severe anti-melanoma differentiation-associatedprotein-5 antibody-positive dermatomyositis. Clinical and Experimental Rheumatology 41: 291-300, No. 2, Feb 2023. Available from: URL: http://​doi.​org/​10.​55563/​clinexprheumatol​/​8kulbf
Metadaten
Titel
Multiple drugs
Infections and off-label use: 3 case reports
Publikationsdatum
01.04.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-37700-4

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Liraglutide

Case report

Gemcitabine

Case report

Multiple drugs

Case report

Azathioprine

Case report

Darbepoetin-alfa